JP2018505658A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018505658A5 JP2018505658A5 JP2017530266A JP2017530266A JP2018505658A5 JP 2018505658 A5 JP2018505658 A5 JP 2018505658A5 JP 2017530266 A JP2017530266 A JP 2017530266A JP 2017530266 A JP2017530266 A JP 2017530266A JP 2018505658 A5 JP2018505658 A5 JP 2018505658A5
- Authority
- JP
- Japan
- Prior art keywords
- gene
- tumor
- rna
- score
- genes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 claims 41
- 206010028980 Neoplasm Diseases 0.000 claims 37
- 230000004547 gene signature Effects 0.000 claims 29
- 239000000523 sample Substances 0.000 claims 25
- 238000000034 method Methods 0.000 claims 21
- 239000000090 biomarker Substances 0.000 claims 18
- 230000014509 gene expression Effects 0.000 claims 17
- 230000004044 response Effects 0.000 claims 15
- 229940124060 PD-1 antagonist Drugs 0.000 claims 10
- 230000006023 anti-tumor response Effects 0.000 claims 10
- 229960002621 pembrolizumab Drugs 0.000 claims 5
- 230000002596 correlated effect Effects 0.000 claims 4
- 230000002601 intratumoral effect Effects 0.000 claims 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 3
- 201000004101 esophageal cancer Diseases 0.000 claims 3
- 238000009396 hybridization Methods 0.000 claims 3
- 206010061424 Anal cancer Diseases 0.000 claims 2
- 208000007860 Anus Neoplasms Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 201000011165 anus cancer Diseases 0.000 claims 2
- 201000009036 biliary tract cancer Diseases 0.000 claims 2
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 2
- 230000000875 corresponding effect Effects 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 201000003733 ovarian melanoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 229960000106 biosimilars Drugs 0.000 claims 1
- 239000012830 cancer therapeutic Substances 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 238000004590 computer program Methods 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 238000002203 pretreatment Methods 0.000 claims 1
- 238000010998 test method Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462089538P | 2014-12-09 | 2014-12-09 | |
| US62/089,538 | 2014-12-09 | ||
| US201562160284P | 2015-05-12 | 2015-05-12 | |
| US62/160,284 | 2015-05-12 | ||
| PCT/US2015/064445 WO2016094377A1 (en) | 2014-12-09 | 2015-12-08 | System and methods for deriving gene signature biomarkers of response to pd-1 antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018505658A JP2018505658A (ja) | 2018-03-01 |
| JP2018505658A5 true JP2018505658A5 (enExample) | 2018-12-27 |
Family
ID=56108044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017530266A Pending JP2018505658A (ja) | 2014-12-09 | 2015-12-08 | Ｐｄ−１アンタゴニストに対する応答の遺伝子シグネチャーバイオマーカーを得るための系および方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11377693B2 (enExample) |
| EP (1) | EP3230498B1 (enExample) |
| JP (1) | JP2018505658A (enExample) |
| KR (1) | KR20170086661A (enExample) |
| CN (1) | CN107109700A (enExample) |
| AU (2) | AU2015360736A1 (enExample) |
| BR (1) | BR112017012222A2 (enExample) |
| CA (1) | CA2968406A1 (enExample) |
| MX (1) | MX2017007535A (enExample) |
| RU (1) | RU2017123117A (enExample) |
| WO (1) | WO2016094377A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE037464T2 (hu) | 2005-12-02 | 2018-08-28 | Icahn School Med Mount Sinai | Nem-natív felületi fehérjéket prezentáló kiméra Newcastle disease vírusok és alkalmazásuk |
| CA2691357C (en) | 2007-06-18 | 2014-09-23 | N.V. Organon | Antibodies to human programmed death receptor pd-1 |
| WO2014158811A1 (en) | 2013-03-14 | 2014-10-02 | Icahn School Of Medicine At Mount Sinai | Newcastle disease viruses and uses thereof |
| AU2014361473B2 (en) | 2013-12-12 | 2019-09-26 | Jiangsu Hengrui Medicine Co., Ltd. | PD-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| JP6857498B2 (ja) | 2014-02-27 | 2021-04-14 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 癌を処置するための併用方法 |
| JP6767096B2 (ja) * | 2014-12-11 | 2020-10-14 | リティックス バイオファーマ エイエス | 免疫チェックポイント阻害剤の組み合わせ |
| WO2016168133A1 (en) | 2015-04-17 | 2016-10-20 | Merck Sharp & Dohme Corp. | Blood-based biomarkers of tumor sensitivity to pd-1 antagonists |
| WO2017177230A1 (en) | 2016-04-08 | 2017-10-12 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| US10438699B2 (en) * | 2016-05-10 | 2019-10-08 | Macau University Of Science And Technology | Method and system for determining an association of biological features with a medical condition |
| EP3523450A1 (en) | 2016-10-07 | 2019-08-14 | Omniseq, Inc. | Methods and systems for determining personalized therapies |
| EP3546591A4 (en) * | 2016-11-24 | 2020-08-12 | Daiichi Sankyo Company, Limited | METHOD FOR PREDICTING SUSCEPTIBILITY OF CANCER TO TREATMENT WITH A PD-1 IMMUNE CHECKPOINT INHIBITOR |
| JOP20190256A1 (ar) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | فيروسات داء نيوكاسل واستخداماتها |
| WO2019200223A1 (en) * | 2018-04-13 | 2019-10-17 | X4 Pharmaceuticals, Inc. | Cancer serum biomarkers and methods of use thereof |
| WO2019213478A1 (en) | 2018-05-04 | 2019-11-07 | Nanostring Technologies, Inc. | Gene expression assay for measurement of dna mismatch repair deficiency |
| EP3793557A1 (en) | 2018-05-14 | 2021-03-24 | Merck Sharp & Dohme Corp. | Biomarkers for a combination therapy comprising lenvatinib and a pd-1 antagonist |
| JP2021524744A (ja) * | 2018-05-21 | 2021-09-16 | ナノストリング テクノロジーズ，インコーポレイティド | 分子遺伝子シグネチャーとその使用方法 |
| WO2020005068A2 (en) * | 2018-06-29 | 2020-01-02 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Gene signatures and method for predicting response to pd-1 antagonists and ctla-4 antagonists, and combination thereof |
| WO2020037215A1 (en) | 2018-08-17 | 2020-02-20 | Icahn School Of Medicine At Mount Sinai | Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease |
| MX2021006578A (es) * | 2018-12-05 | 2021-07-07 | Genentech Inc | Procedimientos de diagnostico y composiciones para la inmunoterapia contra el cancer. |
| JP2022534982A (ja) * | 2019-05-30 | 2022-08-04 | ブリストル－マイヤーズ スクイブ カンパニー | 細胞局在化シグネチャーおよびその使用 |
| US20220290247A1 (en) * | 2019-08-09 | 2022-09-15 | The Regents Of The University Of California | Compositions and methods for diagnosis and treatment of bladder cancer |
| CA3152025A1 (en) | 2019-09-24 | 2021-04-01 | David BRIERE | Combination therapies |
| WO2021091747A1 (en) * | 2019-11-04 | 2021-05-14 | Merck Sharp & Dohme Corp. | ANGIOGENESIS AND mMDSC GENE EXPRESSION BASED BIOMARKER OF TUMOR RESPONSE TO PD-1 ANTAGONISTS |
| EP4069869A1 (en) * | 2019-12-04 | 2022-10-12 | Servicio Andaluz De Salud | Method to predict the response to cancer treatment with anti-pd1 immunotherapy |
| CN111088360A (zh) * | 2020-01-17 | 2020-05-01 | 暨南大学 | Pd1-ctla4和/或pdl2-ctla4在制备预测aml预后试剂盒中的应用 |
| JP2023517956A (ja) | 2020-03-10 | 2023-04-27 | エックス４ ファーマシューティカルズ， インコーポレイテッド | 好中球減少症を処置する方法 |
| TW202227643A (zh) * | 2020-09-18 | 2022-07-16 | 日商小野藥品工業股份有限公司 | 對於免疫檢查點抑制劑之反應的預測方法 |
| EP4225950A4 (en) * | 2020-10-05 | 2025-02-26 | 4C Biomed Limited | Marker for response to pd-1/pd-l1 immunotherapy |
| WO2022135402A1 (zh) * | 2020-12-24 | 2022-06-30 | 信达生物制药(苏州)有限公司 | Pd-l1和/或mhc-2生物标记物在预测肺癌患者治疗疗效中的用途 |
| JP2024526977A (ja) * | 2021-07-22 | 2024-07-19 | アシリア ダイアグノスティックス ベースローテン フェンノートシャップ | 免疫療法後の治療反応のためのバイオマーカー |
| AU2022424122A1 (en) | 2022-01-03 | 2024-07-25 | Checkmate Pharmaceuticals, Inc. | Transcriptional biomarkers for response to innate immune activators |
| EP4540418A1 (en) * | 2022-06-17 | 2025-04-23 | Merck Sharp & Dohme LLC | Genome wide tumor derived gene expression based signatures associated with poor prognosis for melanoma patients with early stage disease |
| WO2024083866A1 (en) | 2022-10-17 | 2024-04-25 | Ultimovacs Asa | Cancer treatment |
| WO2024112609A1 (en) * | 2022-11-21 | 2024-05-30 | Merck Sharp & Dohme Llc | Genome wide tumor derived gene expression based signatures associated with poor prognosis for melanoma patients with early stage disease |
| JPWO2024225488A1 (enExample) * | 2023-04-27 | 2024-10-31 | ||
| WO2025034883A1 (en) | 2023-08-08 | 2025-02-13 | Quanta Therapeutics, Inc. | Combination therapies with kras modulators |
| WO2025106905A1 (en) | 2023-11-17 | 2025-05-22 | Quanta Therapeutics, Inc. | Combination therapies with a kras modulator and an immunomodulator inhibitor |
| WO2025136845A1 (en) * | 2023-12-19 | 2025-06-26 | Merck Sharp & Dohme Llc | Methods of treating a patient with a pd-1 antagonist |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5525464A (en) | 1987-04-01 | 1996-06-11 | Hyseq, Inc. | Method of sequencing by hybridization of oligonucleotide probes |
| US5202231A (en) | 1987-04-01 | 1993-04-13 | Drmanac Radoje T | Method of sequencing of genomes by hybridization of oligonucleotide probes |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| GB8822228D0 (en) | 1988-09-21 | 1988-10-26 | Southern E M | Support-bound oligonucleotides |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5547839A (en) | 1989-06-07 | 1996-08-20 | Affymax Technologies N.V. | Sequencing of surface immobilized polymers utilizing microflourescence detection |
| US5242974A (en) | 1991-11-22 | 1993-09-07 | Affymax Technologies N.V. | Polymer reversal on solid surfaces |
| US5527681A (en) | 1989-06-07 | 1996-06-18 | Affymax Technologies N.V. | Immobilized molecular synthesis of systematically substituted compounds |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US5424186A (en) | 1989-06-07 | 1995-06-13 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis |
| DE3924454A1 (de) | 1989-07-24 | 1991-02-07 | Cornelis P Prof Dr Hollenberg | Die anwendung von dna und dna-technologie fuer die konstruktion von netzwerken zur verwendung in der chip-konstruktion und chip-produktion (dna chips) |
| EP0430881A3 (en) | 1989-11-29 | 1991-10-23 | Ciba-Geigy Ag | Photochromic compounds, process for their preparation and their use |
| US5288644A (en) | 1990-04-04 | 1994-02-22 | The Rockefeller University | Instrument and method for the sequencing of genome |
| US5384261A (en) | 1991-11-22 | 1995-01-24 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis using mechanically directed flow paths |
| US5412087A (en) | 1992-04-24 | 1995-05-02 | Affymax Technologies N.V. | Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces |
| US5324633A (en) | 1991-11-22 | 1994-06-28 | Affymax Technologies N.V. | Method and apparatus for measuring binding affinity |
| DE69322266T2 (de) | 1992-04-03 | 1999-06-02 | Perkin-Elmer Corp., Foster City, Calif. | Proben zusammensetzung und verfahren |
| US5554501A (en) | 1992-10-29 | 1996-09-10 | Beckman Instruments, Inc. | Biopolymer synthesis using surface activated biaxially oriented polypropylene |
| US5503980A (en) | 1992-11-06 | 1996-04-02 | Trustees Of Boston University | Positional sequencing by hybridization |
| DE4311230C2 (de) | 1993-04-02 | 1996-12-19 | Mannesmann Ag | Nicht-spurgebundenes Fahrzeug mit Elektromotor |
| US5837832A (en) | 1993-06-25 | 1998-11-17 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
| US5472672A (en) | 1993-10-22 | 1995-12-05 | The Board Of Trustees Of The Leland Stanford Junior University | Apparatus and method for polymer synthesis using arrays |
| US5470710A (en) | 1993-10-22 | 1995-11-28 | University Of Utah | Automated hybridization/imaging device for fluorescent multiplex DNA sequencing |
| US6156501A (en) | 1993-10-26 | 2000-12-05 | Affymetrix, Inc. | Arrays of modified nucleic acid probes and methods of use |
| US5429807A (en) | 1993-10-28 | 1995-07-04 | Beckman Instruments, Inc. | Method and apparatus for creating biopolymer arrays on a solid support surface |
| US5631734A (en) | 1994-02-10 | 1997-05-20 | Affymetrix, Inc. | Method and apparatus for detection of fluorescently labeled materials |
| US5571639A (en) | 1994-05-24 | 1996-11-05 | Affymax Technologies N.V. | Computer-aided engineering system for design of sequence arrays and lithographic masks |
| US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
| US5624711A (en) | 1995-04-27 | 1997-04-29 | Affymax Technologies, N.V. | Derivatization of solid supports and methods for oligomer synthesis |
| US5545531A (en) | 1995-06-07 | 1996-08-13 | Affymax Technologies N.V. | Methods for making a device for concurrently processing multiple biological chip assays |
| US5661028A (en) | 1995-09-29 | 1997-08-26 | Lockheed Martin Energy Systems, Inc. | Large scale DNA microsequencing device |
| US6022963A (en) | 1995-12-15 | 2000-02-08 | Affymetrix, Inc. | Synthesis of oligonucleotide arrays using photocleavable protecting groups |
| CA2267070A1 (en) | 1996-11-06 | 1998-05-14 | Sequenom, Inc. | Compositions and methods for immobilizing nucleic acids to solid supports |
| DE19782096T1 (de) | 1996-11-06 | 2000-03-23 | Sequenom Inc | Immobiliserung von Nucleinsäuren in hoher Dichte |
| US6077674A (en) | 1999-10-27 | 2000-06-20 | Agilent Technologies Inc. | Method of producing oligonucleotide arrays with features of high purity |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| EP1784501B1 (en) * | 2004-05-14 | 2015-11-18 | Rosetta Genomics Ltd | VIRAL AND VIRUS ASSOCIATED MicroRNAS AND USES THEREOF |
| AU2006244885B2 (en) | 2005-05-09 | 2011-03-31 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| AU2006265108C1 (en) | 2005-07-01 | 2013-01-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
| CA2691357C (en) | 2007-06-18 | 2014-09-23 | N.V. Organon | Antibodies to human programmed death receptor pd-1 |
| WO2009061800A2 (en) * | 2007-11-09 | 2009-05-14 | Genentech, Inc. | Methods and compositions for diagnostic use in cancer patients |
| MX2011002250A (es) | 2008-08-25 | 2011-08-17 | Amplimmune Inc | Antagonistas de muerte celular programada-1 y métodos de uso de los mismos. |
| PT2376535T (pt) | 2008-12-09 | 2017-06-23 | Hoffmann La Roche | Anticorpos anti-pd-l1 e a sua utilização para a melhoria do funcionamento das células t |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| US9404926B2 (en) | 2010-01-29 | 2016-08-02 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Immune gene signatures in cancer |
| KR102031020B1 (ko) | 2011-03-31 | 2019-10-14 | 머크 샤프 앤드 돔 코포레이션 | 인간 프로그램화된 사멸 수용체 pd-1에 대한 항체의 안정한 제제 및 관련된 치료 |
| JP6238459B2 (ja) | 2011-08-01 | 2017-11-29 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法 |
| CA2854921A1 (en) * | 2011-11-23 | 2013-05-30 | Amgen Inc. | Methods of treatment using an antibody against interferon gamma |
| PL2872646T3 (pl) | 2012-07-12 | 2018-03-30 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Sposoby przewidywania czasu przeżycia i responsywności na leczenie pacjenta cierpiącego na nowotwór lity z sygnaturą przynajmniej 7 genów |
| WO2014015011A1 (en) * | 2012-07-19 | 2014-01-23 | Tensorcom, Inc. | Method and apparatus for the alignment of a 60 ghz endfire antenna |
| CA2918608A1 (en) * | 2012-08-03 | 2014-02-06 | Icahn School Of Medicine At Mount Sinai | Biomarker associated with risk of melanoma reoccurrence |
| KR20230070054A (ko) | 2013-03-15 | 2023-05-19 | 제넨테크, 인크. | Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법 |
| WO2014194293A1 (en) | 2013-05-30 | 2014-12-04 | Amplimmune, Inc. | Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof |
| EP3084003A4 (en) | 2013-12-17 | 2017-07-19 | Merck Sharp & Dohme Corp. | Ifn-gamma gene signature biomarkers of tumor response to pd-1 antagonists |
| US20160312295A1 (en) | 2013-12-17 | 2016-10-27 | Merck Sharp & Dohme Corp. | Gene signature biomarkers of tumor response to pd-1 antagonists |
| EP3084005A4 (en) | 2013-12-17 | 2017-08-02 | Merck Sharp & Dohme Corp. | Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists |
| WO2016168133A1 (en) | 2015-04-17 | 2016-10-20 | Merck Sharp & Dohme Corp. | Blood-based biomarkers of tumor sensitivity to pd-1 antagonists |
-
2015
- 2015-12-08 CA CA2968406A patent/CA2968406A1/en not_active Abandoned
- 2015-12-08 EP EP15868101.5A patent/EP3230498B1/en active Active
- 2015-12-08 KR KR1020177018558A patent/KR20170086661A/ko not_active Withdrawn
- 2015-12-08 MX MX2017007535A patent/MX2017007535A/es unknown
- 2015-12-08 WO PCT/US2015/064445 patent/WO2016094377A1/en not_active Ceased
- 2015-12-08 BR BR112017012222A patent/BR112017012222A2/pt not_active Application Discontinuation
- 2015-12-08 JP JP2017530266A patent/JP2018505658A/ja active Pending
- 2015-12-08 AU AU2015360736A patent/AU2015360736A1/en not_active Abandoned
- 2015-12-08 US US15/533,769 patent/US11377693B2/en active Active
- 2015-12-08 RU RU2017123117A patent/RU2017123117A/ru not_active Application Discontinuation
- 2015-12-08 CN CN201580072918.XA patent/CN107109700A/zh active Pending
-
2020
- 2020-07-08 AU AU2020204557A patent/AU2020204557A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018505658A5 (enExample) | ||
| Mohan et al. | Profiling of circulating free DNA using targeted and genome-wide sequencing in patients with SCLC | |
| Chen et al. | Immunological network analysis in HPV associated head and neck squamous cancer and implications for disease prognosis | |
| Zhao et al. | Levels of plasma Epstein-Barr virus DNA prior and subsequent to treatment predicts the prognosis of nasopharyngeal carcinoma | |
| Wong et al. | Poor survival with wild-type TP53 ovarian cancer? | |
| RU2017123117A (ru) | Система и способы получения биомаркеров генных сигнатур ответа на антагонисты pd-1 | |
| Wang et al. | Profiling plasma microRNA in nasopharyngeal carcinoma with deep sequencing | |
| CN103733065A (zh) | 用于癌症的分子诊断试验 | |
| JP2017508970A5 (enExample) | ||
| Popovici et al. | Selecting control genes for RT-QPCR using public microarray data | |
| CN113444804B (zh) | 宫颈癌预后相关基因及其在制备宫颈癌预后预测诊断产品中的应用 | |
| JP2017529859A5 (enExample) | ||
| CN112908470A (zh) | 一种基于rna结合蛋白基因的肝细胞癌预后评分系统及其应用 | |
| CN107974506A (zh) | 一种用于急性髓系白血病药物指示的方法及装置 | |
| CN106148529A (zh) | 与胃癌相关的LncRNA标记物及其专用检测引物、检测方法、试剂盒与应用 | |
| JP2016515800A5 (enExample) | ||
| JP2016073287A (ja) | 腫瘍特性及びマーカーセットの同定のための方法、腫瘍分類、並びに癌のマーカーセット | |
| CN109880905A (zh) | 一组用于三阴性乳腺癌免疫组化分型的基因及其应用 | |
| Miliotis et al. | Determinants of gastric cancer immune escape identified from non-coding immune-landscape quantitative trait loci | |
| Greenberg et al. | Developing a predictive model for metastatic potential in pancreatic neuroendocrine tumor | |
| CN107653312B (zh) | 与血脂水平和冠心病相关的rs7901016检测系统及相关应用 | |
| Shen et al. | Predicting the immune landscape of invasive breast carcinoma based on the novel signature of immune‐related lncRNA | |
| CN108913773A (zh) | 一种临床评价卵巢癌铂类药物化疗敏感性的多分子标志物及其装置与评价方法 | |
| CA2894660C (en) | Method and apparatus for detecting cancer in mammals | |
| CN118711662A (zh) | 一种乳腺癌患者新辅助化疗敏感性的预测装置 |